Media.Player

Matrix metalloproteinase inhibitors to treat tuberculosis

總結

Tuberculosis is an airborne bacterial infection that capitalizes on enzymes produced by the body’s immune system to destroy lung tissue. In particular, the bacteria take advantage of the natural secretion of matrix metalloproteinases (MMPs), which degrade lung tissue and inadvertently facilitate bacterial proliferation. Current tuberculosis treatments consist primarily of antibiotic administration, but are often ineffective in the long term. This technology is an MMP inhibitor that aims to treat tuberculosis by preventing the degradation of lung tissue and subsequent growth of bacteria.

技術優勢

Reduces lung damage due to tuberculosisHinders proliferation of tuberculosis-causing bacteria in infected tissuePatent Information:Patent Pending (US 20140199289)Tech Ventures Reference: IR 2910

技術應用

Tuberculosis therapyTherapy for patients with antibiotic-resistant tuberculosisTherapy for other diseases in which MMPs are implicated in tissue degradation

詳細技術說明

None

*Abstract

None

*Inquiry

Sara GusikColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

2910

*Principal Investigation

*Publications

Elkington P.T., D’Armiento J.M., Friedland J.S. “Tuberculosis Immunopathology: The Neglected Role of Extracellular Matrix Destruction.” Sci Translational Med. 2011 Feb 23;3(71):71ps6Elkington P.T., Shiomi T., Nuttall R.K, Ugarte-Gil C.A., Walker N.F., Saraiva L., Mauri F., Lipman M., Edwards D.R., Robertson B.D., D’Armiento J.M., Friedland J.S. “MMP-1 Drives Immunopathology in Human Tuberculosis and Transgenic Mice.” J Clin Invest. 2011 May 2;121(5):1827-1833

國家/地區

美國